South Korea's Pharma Producers Expand CMO Businesses

---

Researched by Industrial Info Resources (Sugar Land, Texas)--South Korea's pharmaceutical companies are trying to expand their contract manufacturing organization (CMO) businesses. SK Bioscience Company Limited and Humedix Company Limited are expanding plants for the production of COVID-19 vaccines, as well as other items. According to Industrial Info's Global Market Intelligence database, eight projects related to CMO plants are active, with a total investment value of $410.21 million.

Three new plant construction projects represent $297.1 million, and five in-plant expansion and addition projects represent $113.1 million. If you are a subscriber to Industrial Info's Pharma-Biotech database, click here for a list of these projects.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.